[Evaluation of internationally used blood stabilizers for effective erythrocyte substitution].
Haemotherapy developed in the direction of transfusing pure blood cell preparations, if possible and enlarging the therapy with plasma fraction considerably. Quality losses of haemotherapeutics will already occur when they are prepared. This is mainly due to the conditions of blood collecting, blood stabiliser, duration and storage temperature from the blood collecting to further processing as well as biological variability of the composition of the donor's blood. The amount of substrate available to erythrocytes differs in various blood stabilisers. Deplasmatized erythrocyte concentrates can be used after several weeks of storage, if a high glucose concentration is present in the blood stabiliser. In CPD media the function of erythrocytes, the oxygen supply of the tissue, will remain intact a week longer than in ACD media. This effect will be increased by xylitol and pyruvate as well as by adding bicarbonate simultaneously. In future a primary importance will have to be attached to an improved storage of erythrocytes in the form of resuspended buffy coat-free erythrocyte concentrates.
D000225:Adenine; D001692:Biological Transport; D001793:Blood Preservation / Q000379:methods*; D001803:Blood Transfusion / Q000592:standards*; D002951:Citrates; D017707:Erythrocyte Transfusion; D005947:Glucose; D006151:Guanosine; D006801:Humans; D010100:Oxygen / Q000378:metabolism; D010710:Phosphates
D002951:Citrates; D010710:Phosphates; D006151:Guanosine; D005947:Glucose; D000225:Adenine; D010100:Oxygen
Bewertung der international üblichen Blutstabilisatoren für eine effektive Erythrozytensubstitution.